Maximilian Pfisterer

Maximilian Pfisterer

Auto-generated profile, based on publicly available information

Maximilian Pfisterer

Affiliation Institute of Biochemistry, Justus-Liebig-University, Giessen, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2025 in Cell Death & Differentiation
Verified
Journal Article
Open access
PDF file
JDJan Dreute
Jan Dreute
JSJulia Stengel
Julia Stengel
JBJonas Becher
Jonas Becher
DBDavid van Den Borre
David van Den Borre
MPMaximilian Pfisterer
Maximilian Pfisterer
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, BMS-986205, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), also restricts oxidative phosphorylation (OXPHOS), as revealed here. BMS-986205, which is being tested in multiple Phase III clinical trials, inhibits the ubiquinone reduction site of respiratory complex I and thus compromises mitochondrial ATP production. The energetic catastrophe caused by simultaneous interference with glycolysis and OXPHOS resulted in either cell death or the induction of senescence in tumor cells, with the latter being eliminated by senolytics. The frequent synergy observed with combined inhibitor treatment was comprehensively confirmed through testing on tumor cell lines from the DepMap panel and on human colorectal cancer organoids. These experiments revealed highly synergistic activity of the compounds in a third of the tested tumor cell lines, correlating with alterations in genes with known roles in metabolic regulation and demonstrating the therapeutic potential of metabolic intervention.

29 May 2024 in Open Biology
Verified
Journal Article
Open access
MPMaximilian Pfisterer
Maximilian Pfisterer
RRRoman Robert
Roman Robert
VSVera Saul
Vera Saul
APAmelie Pritz
Amelie Pritz
MSMarkus Seibert
Markus Seibert
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
The precise spatial and temporal control of histone phosphorylations is important for the ordered progression through the different phases of mitosis. The phosphorylation of H2B at S6 (H2B S6ph), which is crucial for chromosome segregation, reaches its maximum level during metaphase and is limited to the inner centromere. We discovered that the temporal and spatial regulation of this modification, as well as its intensity, are governed by the scaffold protein RepoMan and its associated catalytically active phosphatases, PP1α and PP1γ. Phosphatase activity is inhibited at the area of maximal H2B S6 phosphorylation at the inner centromere by site-specific Aurora B-mediated inactivation of the PP1/RepoMan complex. The motor protein Mklp2 contributes to the relocalization of Aurora B from chromatin to the mitotic spindle during anaphase, thus alleviating Aurora B-dependent repression of the PP1/RepoMan complex and enabling dephosphorylation of H2B S6. Accordingly, dysregulation of Mklp2 levels, as commonly observed in tumour cells, leads to the lack of H2B S6 dephosphorylation during early anaphase, which might contribute to chromosomal instability.

1 March 2022 in Heliyon
Verified
Journal Article
Open access
MSM. Lienhard Schmitz
M. Lienhard Schmitz
JDJan Dreute
Jan Dreute
MPMaximilian Pfisterer
Maximilian Pfisterer
SGStefan Günther
Stefan Günther
MKMichael Kracht
Michael Kracht
SCShashipavan Chillappagari
Shashipavan Chillappagari
The functionally redundant ubiquitin E3 ligases SIAH1 and SIAH2 have been implicated in the regulation of metabolism and the hypoxic response, while their role in other signal-mediated processes such inflammatory gene expression remains to be defined. Here we have downregulated the expression of both SIAH proteins with specific siRNAs and investigated the functional consequences for IL-1α-induced gene expression. The knockdown of SIAH1/2 modulated the expression of approximately one third of IL-1α-regulated genes. These effects were not due to changes in the NF-κB and MAPK signaling pathways and rather employed further processes including those mediated by the coactivator p300. Most of the proteins encoded by SIAH1/2-regulated genes form a regulatory network of proinflammatory factors. Thus SIAH1/2 proteins function as variable rheostats that control the amplitude rather than the principal activation of the inflammatory gene response.

18 June 2025 in EMBO Reports
Verified
Journal Article
Open access
MPMaximilian Pfisterer
Maximilian Pfisterer
JDJan Dreute
Jan Dreute
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
The well-studied NF-κB signaling system is a key mediator of the inflammatory response. Large-scale sequencing studies in humans now allow initial insights into non-essential human genes in which both alleles carry mutations that prevent protein expression or function. Here, we compiled the non-essential genes identified in various sequencing studies and analyzed the occurrence of knockouts in the human NF-κB signaling system. This revealed a lower knockout frequency in the NF-κB system compared to the entire genome. Since drugs inhibiting NF-κB pathway components were unsuccessful in clinical trials so far, the naturally occurring knockouts of NF-κB and its upstream regulators could provide new candidates for therapeutic intervention. To investigate the potential functional importance of posttranslational modifications (PTMs) occurring on NF-κB components, we analyzed not only their evolutionary conservation but also, as a second criterion, their genetic constraint in the sequenced individuals. This approach revealed the absence of missense mutations at key modification sites involved in NF-κB activation and identified additional candidate sites for future studies.

8 May 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
JDJan Dreute
Jan Dreute
JSJulia Stengel
Julia Stengel
JBJonas Becher
Jonas Becher
DBDavid V. D. Borre
David V. D. Borre
MPMaximilian Pfisterer
Maximilian Pfisterer
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
As cancer cell specific rewiring of metabolic networks creates potential therapeutic opportunities, we conducted a synthetic lethal screen utilizing inhibitors of metabolic pathways. Simultaneous administration of (R)-GNE-140 and BMS-986205 (Linrodostat) preferentially halted proliferation of ovarian cancer cells, but not of their non-oncogenically transformed progenitor cells. While (R)-GNE-140 inhibits lactate dehydrogenase (LDH)A/B and thus effective glycolysis, BMS-986205, in addition to its known inhibitory activity on Indoleamine 2,3-dioxygenase (IDO1), also restricts oxidative phosphorylation (OXPHOS), as revealed here. BMS-986205, which is being tested in multiple Phase III clinical trials, inhibits the ubiquinone reduction site of respiratory complex I and thus compromises mitochondrial ATP production. The energetic catastrophe caused by simultaneous interference with glycolysis and OXPHOS resulted in either cell death or the induction of senescence in tumor cells, with the latter being eliminated by senolytics. The frequent synergy observed with combined inhibitor treatment was comprehensively confirmed through testing on tumor cell lines from the DepMap panel and on human colorectal cancer organoids. These experiments revealed highly synergistic activity of the compounds in a third of the tested tumor cell lines, correlating with alterations in genes with known roles in metabolic regulation and demonstrating the therapeutic potential of metabolic intervention.

10 February 2026 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MPMaximilian Pfisterer
Maximilian Pfisterer
APAmelie Pritz
Amelie Pritz
APAnna Parry
Anna Parry
Lienhard SchmitzLienhard Schmitz
Lienhard Schmitz
Histone replacement systems are valuable tools for studying histone modifications, but in vertebrates this is so far only possible by labor-intensive CRISPR base editing of each single histone gene. To facilitate such studies, we developed an alternative method and conducted proof-of-principle experiments using histone 2B (H2B) as an example. This method relies on shRNA targeted degradation of endogenous histone mRNA and simultaneous re-expression of a replacement histone. Due to their limited histone gene number, chicken cells proved suitable as a tetrapod model system for this approach. In the first-generation system we developed an shRNA design tool that identified shRNAs leading to efficient downregulation of each of the canonical histones using a single doxycycline (Dox)-inducible shRNA. As H2B knockdown cells are not viable, they were rescued by simultaneous Dox-inducible re-expression of H2B. Since the comparability between wild-type and mutated histone variants is limited due to random chromosomal integration, we developed a second-generation “inducible knockdown-re-expression” system. This new version employs genomic landing pads to facilitate Bxb1 recombinase-mediated cassette exchange with mutated histones. The system successfully rescued reconstituted cells from histone depletion-induced cell death, but requires optimization to align histone expression levels with endogenous levels. Overall, this system offers a promising new method for studying specific histone modifications in chicken cells.